SCOTTSDALE, AZ, United States, via ETELIGIS INC., 11/05/2014 – – AirWare Labs Corp. (OTCQB: AIRW) today announced the filing of a new patent application for a cutting-edge CPAP (Continuous Positive Airway Pressure) treatment system that replaces bulky, uncomfortable CPAP masks with a streamlined nasal design that promotes a restful night’s sleep.
The system will utilize AirWare Labs’ proprietary nasal oxygen cannula design, fitted with disposable dilators that work to open the nasal passage and increase airflow by up to 60%.
Commonly prescribed for patients with breathing problems like sleep apnea, CPAP therapy uses forced air pressure to keep airways open and improve breathing while the patient is asleep. Conventional CPAP masks cover the patient’s nose and mouth with straps that stretch across the forehead and face. While the masks can be effective in treating sleep apnea, common complaints include feelings of claustrophobia, chest discomfort, skin irritation, dry nose and mouth. Additionally, improperly fitted masks can fail to provide the air pressure necessary for keeping the airway open, and can even release air into the eyes, causing dryness and irritation. AirWare Labs’ nasal system ensures a proper fit, eliminates discomfort and allows for ease of movement.
“The complaints and physical discomfort associated with conventional CPAP masks often result in a patient’s refusal to use them, which defeats the whole purpose,” said Dan Pool, Vice President of Product Development for AirWare Labs. “By creating a CPAP mask system that gently and comfortably fits the nose instead of over the entire face, we’re putting an end to the claustrophobia and chest discomfort that mask wearers experience. Even more, our high flow nasal cannula diffuses the flow of air as it enters the nasal passage, so it effectively eliminates dryness and irritation as well.”
Because regular cleaning and/or replacement of CPAP materials is required to reduce the risks of bacterial contamination and infection, the retail cost of conventional supplies—including the mask, tubes and filters—can average as much as $800 per year per patient. AirWare Labs’ system will utilize inexpensive disposable nasal cannula inserts, saving patients hundreds of dollars each year in maintenance and replacement costs.
“When we examined all of the problems and costs associated with conventional CPAP mask systems, we saw a clear need for a better solution,” said Jeffrey Rassás, CEO of AirWare Labs. “Our patent pending CPAP nasal mask system will provide a much-needed alternative for millions of patients who find masks to be too uncomfortable, cumbersome or expensive.”
According to the National Sleep Foundation (http://sleepfoundation.org/sleep-disorders-problems/sleep-apnea), more than 18 million adults in the U.S. have sleep apnea. A recent market research report (http://www.micromarketmonitor.com/market-report/positive-airway-pressure-pap-reports-7582754989.html) valued the global Positive Airway Pressure (PAP) market at $4.7 billion in 2013 and forecasted that value to grow to $10.4 billion by 2018.
About AirWare Labs Corporation:
AirWare Labs Corp. (publicly traded as OTCQB: AIRW) provides patented and innovative technology solutions for consumer products that promote better health through breathing and enhanced wellbeing. AirWare Labs’ products are marketed under the brand name of AIR®. AIR® products utilize an FDA approved medical grade material, molded as an intranasal Air Breathe dilator, to act as the delivery system. This AIR® microstructure enhances normal nasal airflow with every breath — clinically proven to deliver up to 40% more oxygen.
Some AIR® products are infused with essential oils with unique healing properties including antibacterial and therapeutic defense against airborne allergens, viruses and bacteria. AIR® Allergy and Travel products provide additional defense in the form of an integrated filter media from 3M to remove microscopic particles that carry viruses, allergens and bacteria. Other AIR® specialty products help provide performance enhancements and relief from congestion, insomnia, headaches, nausea, and snoring. For more product information, please visit: http://www.airwarelabs.com or company information visit: http://airwarelabscorp.com.
The statements in this press release regarding any implied or perceived benefits from the release by AirWare Labs Corp. of its products are forward-looking statements. Such statements involve risks and uncertainties, including, but not limited to, risks and effects of legal and administrative proceedings and governmental regulation, especially in a foreign country, future financial and operational results, competition, general economic conditions, and the ability to manage and continue growth.
Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual outcomes may vary materially from those indicated. Important factors that could cause actual results to differ materially from the forward-looking statements we make in this news release include the introduction of new technology, market conditions and those set forth in reports or documents we file from time to time with the SEC. We undertake no obligation to revise or update such statements to reflect current events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.
SOURCE: AirWare Labs, Corp.